Skip to main content
BayerIn development

Bayer's Sunharbo Green Light Shifts the Debate From Pipeline Promise to Profit Proof

Source: Autobound Signal API · 70 signals tracked for Bayer · updated

Get Bayer's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bayer this week? Use Autobound signals for bayer.com.

What happened

Bayer's Sevabertinib was authorized in China for first-line treatment of adults with advanced HER2-mutated non-small cell lung cancer.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Bayer investors have spent the past week weighing two very different kinds of news: a regulatory milestone for its pharmaceutical arm and a courtroom reprieve for its embattled crop-science division. The market's reaction has been split down the middle, with two major research houses landing on opposite sides of the same stock. Jefferies reiterated its "Hold" rating on Bayer with a price target of EUR 48.50, a level the shares have already left behind - the stock was trading at EUR 56.70. Deutsche Bank Research, by contrast, raised its target from EUR 60 to EUR 65 and stuck with its "Buy" recommendation, placing its mark comfortably above the current quote. The more consequential development came on Monday, when the FDA cleared SUNHARBO, whose active ingredient is asundexian, for reducing stroke risk in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The approval covers use in combination with an antiplatelet therapy. Bayer expects shipments to begin between mid- and late November. The company bills the drug as the world's first approved factor XIa inhibitor, a designation underpinned by the Phase III OCEANIC-STROKE trial. A second regulatory win arrived just days earlier in China, where Sevabertinib was authorized for first-line treatment of adults with advanced HER2-mutated non-small cell lung cancer. Should investors...

Keep reading with a free account

The rest of this article, and every signal for Bayer, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Sevabertinib
Location
China

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
90%
Detected
Nov 11, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Bayer and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bayer this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/51c0047a-221d-2374-384d-11302b32345d returns this record as JSON. POST /v1/companies/enrich returns every signal for bayer.com.

{
  "signal_id": "51c0047a-221d-2374-384d-11302b32345d",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-11T20:31:21+00:00",
  "company": {
    "name": "Bayer",
    "domain": "bayer.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/bayer-s-sunharbo-green-light-shifts-the-debate-from-pipeline-promise-to-profit-proof/70494233",
    "title": "Bayer's Sunharbo Green Light Shifts the Debate From Pipeline Promise to Profit Proof - ad-hoc-news.de",
    "excerpt": "Bayer investors have spent the past week weighing two very different kinds of news: a regulatory milestone for its pharmaceutical arm and a courtroom reprieve for its embattled crop-science division. The market's reaction has been split down the middle, with two major research houses landing on opposite sides of the same stock. Jefferies reiterated its \"Hold\" rating on Bayer with a price target of EUR 48.50, a level the shares have already left behind - the stock was trading at EUR 56.70. Deutsche Bank Research, by contrast, raised its target from EUR 60 to EUR 65 and stuck with its \"Buy\" recommendation, placing its mark comfortably above the current quote. The more consequential development came on Monday, when the FDA cleared SUNHARBO, whose active ingredient is asundexian, for reducing stroke risk in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The approval covers use in combination with an antiplatelet therapy. Bayer expects shipments to begin between mid- and late November. The company bills the drug as the world's first approved factor XIa inhibitor, a designation underpinned by the Phase III OCEANIC-STROKE trial. A second regulatory win arrived just days earlier in China, where Sevabertinib was authorized for first-line treatment of adults with advanced HER2-mutated non-small cell lung cancer. Should investors...",
    "product": "Sevabertinib",
    "summary": "Bayer's Sevabertinib was authorized in China for first-line treatment of adults with advanced HER2-mutated non-small cell lung cancer.",
    "location": "China",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2672462_1200_675.webp",
    "confidence": 0.9,
    "product_data": {
      "name": "Sevabertinib",
      "full_text": "Sevabertinib",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-11T20:31:21Z",
    "location_data": [
      {
        "region": "Eastern Asia",
        "country": "China",
        "continent": "Asia",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "A second regulatory win arrived just days earlier in China, where Sevabertinib was authorized for first-line treatment of adults with advanced HER2-mutated non-small cell lung cancer."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.